Addressing the challenge: Current and future directions in ovarian cancer therapy

Current Gene Therapy

Volumn 9, Issue 6, 2009, Pages 434-458

  Kaur, Tranum ^a   Slavcev, Roderick A ^a   Wettig, Shawn D ^a  

^a UNIVERSITY OF WATERLOO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BETA 2 MICROGLOBULIN; BRCA1 PROTEIN; CARCINOEMBRYONIC ANTIGEN MONOCLONAL ANTIBODY; CNTO 95; E1A PROTEIN; EC 90; ENTRACEPT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUCYTOSINE; GANCICLOVIR; HLA B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; LIPOSOME; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MUCIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAKED DNA; NANOPARTICLE; ONYX 015; PROTEIN P53; REMOVAB; SMALL INTERFERING RNA; SOMATOSTATIN RECEPTOR; TEMSIROLIMUS; THYMIDINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG TARGETING; GENE EXPRESSION; GENE EXPRESSION SYSTEM; GENE GUN; GENE SILENCING; GENE TARGETING; HUMAN; MICROBUBBLE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SUICIDE GENE THERAPY; SYSTEMIC DISEASE;

ADJUVANTS, IMMUNOLOGIC; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE THERAPY; GENES, TUMOR SUPPRESSOR; GENETIC VECTORS; HUMANS; OVARIAN NEOPLASMS; TRANSGENES;

EID: 73449120735     PISSN: 15665232     EISSN: None     Source Type: Journal    
DOI: 10.2174/156652309790031148     Document Type: Review

References (214)

1. Kaur M, Radovanovic A, Essack M, et al. Database for exploration of functional context of genes implicated in ovarian cancer. Nucleic Acids Res 2009; 37: D820-D23.
2. Bertenshaw GP, Yip P, Seshaiah P, et al. Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol Biomarkers 2008; 17: 2872-81.
3. Christie M, Oehler MK. Molecular pathology of epithelial ovarian cancer. J Br Menopause Soc 2006; 12: 57-63.
4. Corney DC, Nikitin AY. MicroRNA and ovarian cancer. Histol Histopathol 2008; 23: 1161-9.
5. Lane DP, Crawford LV. T-Antigen Is Bound to a Host Protein in Sv40-Transformed Cells. Nature 1979; 278: 261-3.
6. Hainaut P, Vahakangas K. p53 as a sensor of carcinogenic exposures: mechanisms of p53 protein induction and lessons from p53 gene mutations. Pathol Biol (Paris) 1997; 45: 833-44.
7. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
8. Olivier M, Eeles R, Hollstein M, et al. The IARC TP53 database: New Online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.
9. Lane DP. Cancer - P53, guardian of the genome. Nature 1992; 358: 15-16.
10. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8: 345-57.
11. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992; 1: 45-9.
12. Zhan QM, Bae I, Kastan MB, Fornace AJ. The P53-dependent gamma-ray response of Gadd45. Cancer Res 1994; 54: 2755-60.
13. Ruley HE. p53 and response to chemotherapy and radiotherapy. Important Adv Oncol 1996: 37-56.
14. Chiarugi V, Magnelli L, Cinelli M, Ruggiero M. Oncogenes, p53, and tumor angiogenesis. J Cancer Res Clin 1998; 124: 523-5.
15. Lowe SW, Bodis S, Mcclatchey A, et al. P53 Status and the efficacy of cancer-therapy in vivo. Science 1994; 266: 807-10.
16. Chang EH, Pirollo KF, Bouker KB. Tp53 gene therapy: a key to modulating resistance to anticancer therapies? Mol Med Today 2000; 6: 358-64.
17. Casado E, Gomez-Navarro J, Yamamoto M, et al. Strategies to accomplish targeted expression of transgenes in ovarian cancer for molecular therapeutic applications. Clin Cancer Res 2001; 7: 2496-504.
18. Collinet P, Lanvin D, Vereecque R, Quesnel B, Querleu D. Gene therapy and ovarian cancer: update of clinical trials. J Gynecol Obstet Biol Reprod (Paris) 2000; 29: 532-7.
19. Collinet P, Vereecque R, Sabban F, et al. In vivo expression and antitumor activity of p53 gene transfer with naked plasmid DNA in an ovarian cancer xenograft model in nude mice. J Obstet Gynaecol Re 2006; 32: 449-53.
20. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-Gene - Deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J Clin Oncol 2002; 20: 1562-9.
21. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-70.
22. Lam JT, Bauerschmitz GJ, Kanerva A, et al. Replication of an integrin targeted conditionally replicating adenovirus on primary ovarian cancer spheroids. Cancer Gene Ther 2003; 10: 377-87.
23. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? Lancet Oncol 2003; 4: 415-22.
24. Blaese RM. Gene therapy for cancer. Sci Am 1997; 276: 111-5.
25. Moolten FL. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes - paradigm for a prospective cancer control strategy. Cancer Res 1986; 46: 5276-81.
26. Rogulski KR, Zhang K, Kolozsvary A, Kim JH, Freytag SO. Pronounced antitumor effects and tumor radiosensitization of double suicide gene therapy. Clin Cancer Res 1997; 3: 2081-8.
27. Xie Y, Gilbert JD, Kim JH, Freytag SO. Efficacy of adenovirus-mediated CD/5-FC and HSV-1 thymidine kinase/ganciclovir suicide gene therapies concomitant with p53 gene therapy. Clin Cancer Res 1999; 5: 4224-32.
28. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother 1997; 20: 165-77.
29. Connor J, Bannerji R, Saito S, et al. Regression of bladder-tumors in mice treated with interleukin-2 gene-modified tumor-cells. J Exp Med 1993; 177: 1127-34.
30. Sun Y, Jurgovsky K, Moller P, et al. Vaccination with IL-12 gene-modified autologous melanoma cells: preclinical results and a first clinical phase I study. Gene Ther 1998; 5: 481-90.
31. Rosenberg SA. A new era of cancer immunotherapy: Converting theory to performance. CA Cancer J Clin 1999; 49: 70-73.
32. Marshall JL, Hoyer RJ, Toomey MA, et al. Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000; 18: 3964-73.
33. Qian HN, Liu GZ, Cao SJ, Feng J, Ye X. The experimental study of ovarian carcinoma vaccine modified by human B7-1 and IFN-gamma genes. Int J Gynecol Cancer 2002; 12: 80-5.
34. Guckel B, Meyer GC, Rudy W, et al. Interleukin-12 requires initial CD80-mediated T-cell activation to support immune responses toward human breast and ovarian carcinoma. Cancer Gene Ther 1999; 6: 228-37.
35. Guan J, Ma LJ, Wei LH. Characteristics of ovarian cancer cells transduced by the bicistronic retroviral vector containing GM-CSF and HSV-TK genes. Chinese Med J-Peking 2001; 114: 147-51.
36. Zhang J, Chen AP, Wang B, et al. Correlations of EGFR and LRP to chemotherapy resistance and prognosis of ovarian cancer. Ai Zheng 2008; 27: 1331-6.
37. Finkler N, Gordon A, Crozier M, et al. Phase 2 Evaluation of OSI-774, a Potent Oral Antagonist of the EGFR-TK in Patients with advanced ovarian carcinoma. Proc Am Soc Clin Oncol 2001; 20: Abstract 831.
38. Wagner U, du Bois A, Pfisterer J, et al. Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy- A phase II trial of the AGO ovarian cancer study group (AGO-OVAR 2.6). Gynecol Oncol 2007; 105: 132-7.
39. Berek JS, Schultes BC, Nicodemus CF. Biologic and immunologic therapies for ovarian cancer. J Clin Oncol 2003; 21: 168s-74s.
40. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655-7.
41. Hu LM, Hofmann J, Jaffe RB. Phosphatidylinostol 3-kinase mediates angiogenesis and vascular permeability associated with ovarian carcinoma. Clin Cancer Res 2005; 11: 8208-12.
42. Campbell IG, Russell SE, Choong DYH, et al. Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res 2004; 64: 7678-81.
43. Vega F, Medeiros LJ, Leventaki V, et al. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Cancer Res 2006; 66: 6589-97.
44. Elit L. CCI-779 Wyeth. Curr Opin Investig Drugs 2002; 3: 1249-53.
45. Fountaine TM, Wood MJA, Wade-Martins R. Delivering RNA interference to the mammalian brain. Curr Gene Ther 2005; 5: 399-410.
46. Faltus T, Yuan J, Zimmer B, et al. Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia 2004; 6: 786-95.
47. El-Naggar SM, Malik MT, Kakar SS. Small interfering RNA against PTTG: A novel therapy for ovarian cancer. Int J Oncol 2007; 31: 137-43.
48. Naylor MS, Stamp GW, Davies BD, Balkwill FR. Expression and activity of Mmps and their regulators in ovarian-cancer. Int J Cancer 1994; 58: 50-6.
49. Davidson B, Berner A, Nesland JM, et al. E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions. J Pathol 2000; 192: 460-9.
50. Azad NS, Posadas EM, Kwitkowski VE, et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008; 26: 3709-14.
51. Duan ZF, Weinstein EJ, Ji D, et al. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther 2008; 7: 2377-85.
52. Deisseroth AB, Kavanagh J, Champlin R. Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: a pilot trial. Hum Gene Ther 1994; 5: 1507-22.
53. Gendler SJ. MUC1, the renaissance molecule. J Mammary Gland Biol 2001; 6: 339-53.
54. Gupta VK, Park JO, Kurihara T, et al. Selective gene expression using a DF3/MUC1 promoter in a human esophageal adenocarcinoma model. Gene Ther 2003; 10: 206-12.
55. Tai YT, Strobel T, Kufe D, Cannistra SA. In vivo cytotoxicity of ovarian cancer cells through tumor-selective expression of the BAX gene. Cancer Res 1999; 59: 2121-6.
56. Manome Y, Abe M, Hagen MF, Fine HA, Kufe DW. Enhancer sequences of the Df3 gene regulate expression of the herpessimplex virus thymidine kinase gene and confer sensitivity of human breast-cancer cells to ganciclovir. Cancer Res 1994; 54: 5408-13.
57. Teoh G, Chen L, Urashima M, et al. Adenovirus vector-based purging of multiple myeloma cells. Blood 1998; 92: 4591-601.
58. Guan HH, Budzynski W, Koganty RR, et al. Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998; 9: 451-8.
59. Tait DL, Obermiller PS, Jensen RA, Holt JT. Ovarian cancer gene therapy with a BRCA1 retroviral vector. Cancer Gene Ther 1999; 6: S1.
60. Yew NS, Zhao HM, Wu IH, et al. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 2000; 1: 255-62.
61. Hartikka J, Sawdey M, Cornefert-Jensen F, et al. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum Gene Ther 1996; 7: 1205-17.
62. Herweijer H, Zhang GF, Subbotin VM, et al. Time course of gene expression after plasmid DNA gene transfer to the liver. J Gene Med 2001; 3: 280-91.
63. Bigger BW, Tolmachov O, Collombet JM, et al. An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy. J Biol Chem 2001; 276: 23018-27.
64. Darquet AM, Rangara R, Kreiss P, et al. Minicircle: an improved DNA molecule for in vitro and in vivo gene transfer. Gene Ther 1999; 6: 209-18.
65. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Mol Ther 2003; 8: 495-500.
66. Darquet AM, Cameron B, Wils P, Scherman D, Crouzet J. A new DNA vehicle for nonviral gene delivery: supercoiled minicircle. Gene Ther 1997; 4: 1341-9.
67. Wittig B, Marten A, Dorbic T, et al. Therapeutic vaccination against metastatic carcinoma by expression-modulated and immunomodified autologous tumor cells: a first clinical phase I/II trial. Hum Gene Ther 2001; 12: 267-78.
68. Schakowski F, Gorschluter M, Junghans C, et al. A novel minimalsize vector (MIDGE) improves transgene expression in colon carcinoma cells and avoids transfection of undesired DNA. Mol Ther 2001; 3: 793-800.
69. Schakowski F, Gorschluter M, Buttgereit P, et al. Minimal size MIDGE vectors improve transgene expression in vivo. In Vivo 2007; 21: 17-23.
70. Liu F, Huang L. Development of non-viral vectors for systemic gene delivery. J Control Rel 2002; 78: 259-66.
71. El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Rel 2004; 94: 1-14.
72. Liu C, Zhang N. Pharmaceutical strategies enhancing cell penetration efficiencies of non-viral gene delivery systems. Curr Gene Ther 2009.
73. Branca MA. Gene therapy: cursed or inching towards credibility? Nat Biotechnol 2005; 23: 519-21.
74. Montier T, Benvegnu T, Jaffres PA, Yaouanc JJ, Lehn P. Progress in cationic lipid-mediated gene transfection: a series of bio-inspired lipids as an example. Curr Gene Ther 2008; 8: 296-312.
75. Brigham KL, Meyrick B, Christman B, et al. In vivo transfection of murine lungs with a functioning prokaryotic gene using a liposome vehicle. Am J Med Sci 1989; 298: 278-81.
76. Nabel GJ, Nabel EG, Yang ZY, et al. Direct gene-transfer with dna liposome complexes in melanoma - expression, biologic activity, and lack of toxicity in humans. Proc Natl Acad Sci USA 1993; 90: 11307-11.
77. Wolff JA, Budker V. The mechanism of naked DNA uptake and expression. Adv Genet 2005; 54: 3-20.
78. Wolff JA, Malone RW, Williams P, et al. Direct gene-transfer into mouse muscle In vivo. Science 1990; 247: 1465-8.
79. Braun S. Muscular Gene Transfer Using Nonviral Vectors. Curr Gene Ther 2008; 8: 391-405.
80. Acsadi G, Jiao S, Jani A, et al. Direct Gene-Transfer and Expression into rat-heart In vivo. N Biol 1991; 3: 71-81.
81. Hengge UR, Walker PS, Vogel JC. Expression of naked DNA in human, pig, and mouse skin. J Clin Invest 1996; 97: 2911-6.
82. Li K, Welikson RE, Vikstrom KL, Leinwand LA. Direct gene transfer into the mouse heart. J Mol Cell Cardiol 1997; 29: 1499-504.
83. Zhang GF, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-37.
84. Lewis DL, Hagstrom JE, Loomis AG, Wolff JA, Herweijer H. Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet 2002; 32: 107-8.
85. McCaffrey AP, Meuse L, Pham TTT, et al. Gene expression - RNA interference in adult mice. Nature 2002; 418: 38-39.
86. Coll JL, Negoescu A, Louis N, et al. Antitumor activity of bax and p53 naked gene transfer in lung cancer: In vitro and in vivo analysis. Hum Gene Ther 1998; 9: 2063-74.
87. Felgner PL, Gadek TR, Holm M, et al. Lipofection - a highly efficient, lipid-mediated DNA-transfection procedure. Proc Natl Acad Sci USA 1987; 84: 7413-7.
88. Barteau B, Chevre R, Letrou-Bonneval E, et al. Physicochemical parameters of non-viral vectors that govern transfection efficiency. Curr Gene Ther 2008; 8: 313-23.
89. Clark PR, Hersh EM. Cationic lipid-mediated gene transfer: current concepts. Curr Opin Mol Ther 1999; 1: 158-76.
90. Huang L, Viroonchatapan E. Introduction, in nonviral vectors for gene therapy. Huang L, Hung M-C, Wagner E, Eds. San Diego, Academic Press: 1999; pp. 3-22.
91. Barron LG, Szoka FCJ. The perplexing delivery mechanism of lipoplexes, in nonviral vectors for gene therapy. Huang L, Hung MC, Wagner E, Eds. San Diego: Academic Press, 1999; pp. 229-66.
92. Zou YY, Zong G, Ling YH, et al. Effective treatment of early endobronchial cancer with regional administration of liposome-p53 complexes. J Natl Cancer I 1998; 90: 1130-7.
93. Kim CK, Choi EJ, Choi SH, et al. Enhanced p53 gene transfer to human ovarian cancer cells using the cationic nonviral vector, DDC. Gynecol Oncol 2003; 90: 265-72.
94. Lesoonwood LA, Kim WH, Kleinman HK, Weintraub BD, Mixson AJ. Systemic gene-therapy with P53 reduces growth and metastases of a malignant human breast-cancer in nude-mice. Hum Gene Ther 1995; 6: 395-405.
95. Chen QR, Mixson AJ. Systemic gene therapy with p53 inhibits breast cancer: recent advances and therapeutic implications. Front Biosci 1998; 3: D997-D1004.
96. Xu M, Kumar D, Srinivas S, et al. Parenteral gene therapy with p53 inhibits human breast tumors in vivo through a bystander mechanism without evidence of toxicity. Hum Gene Ther 1997; 8: 177-85.
97. Midoux P, Breuzard G, Gomez JP, Pichon C. Polymer-based gene delivery: a current review on the uptake and intracellular trafficking of polyplexes. Curr Gene Ther 2008; 8: 335-52.
98. Choosakoonkriang S, Lobo BA, Koe GS, Koe JG, Middaugh CR. Biophysical characterization of PEI/DNA complexes. J Pharm Sci 2003; 92: 1710-22.
99. Merlin JL, Dolivet G, Dubessy C, et al. Improvement of nonviral p53 gene transfer in human carcinoma cells using glucosylated polyethylenimine derivatives. Cancer Gene Ther 2001; 8: 203-10.
100. Poulain L, Ziller C, Muller CD, et al. Ovarian carcinoma cells are effectively transfected by polyethylenimine (PEI) derivatives. Cancer Gene Ther 2000; 7: 644-52.
101. Jin P, Kong BH. Inhibitory effect of polyethylenimine-mediated transfection of suicide gene HSV-tk with an ovarian-specific promoter on growth of ovarian cancer cell line SKOV3. Ai Zheng 2005; 24: 806-11.
102. Han JH, Lim MJ, Yeom YI. Receptor-mediated gene transfer to cells of hepatic origin by galactosylated albumin-polylysine complexes. Biol Pharm Bull 1999; 22: 836-40.
103. Hildebrandt IJ, Iyer M, Wagner E, Gambhir SS. Optical imaging of transferrin targeted PEI/DNA complexes in living subjects. Gene Ther 2003; 10: 758-64.
104. Kunath K, von Harpe A, Fischer D, Kissel T. Galactose-PEI-DNA complexes for targeted gene delivery: degree of substitution affects complex size and transfection efficiency. J Control Rel 2003; 88: 159-72.
105. Guo W, Lee RL. Receptor-targeted gene delivery via folate-conjugated polyethylenimine. AAPS PharmSci 1999; 1: E19.
106. Guo WJ, Lee RJ. Efficient gene delivery via non-covalent complexes of folic acid and polyethylenimine. J Control Rel 2001; 77: 131-8.
107. Brunner S, Sauer T, Carotta S, et al. Cell cycle dependence of gene transfer by lipoplex polyplex and recombinant adenovirus. Gene Ther 2000; 7: 401-7.
108. Whitmore M, Li S, Huang L. LPD lipopolyplex initiates a potent cytokine response and inhibits tumor growth. Gene Ther 1999; 6: 1867-75.
109. Mastrobattista E, Kapel RHG, Eggenhuisen MH, et al. Lipidcoated polyplexes for targeted gene delivery to ovarian carcinoma cells. Cancer Gene Ther 2001; 8: 405-13.
110. Zeisser-Labouebe M, Delie F, Gurny R, Lange N. Benefits of nanoencapsulation for the hypercin-mediated photodetection of ovarian micrometastases. Eur J Pharm Biopharm 2009; 71: 207-13.
111. Riedl CR, Plas E, Pfluger H. Fluorescence detection of bladder tumors with 5-amino-levulinic acid. J Endourol 1999; 13: 755-9.
112. Claydon PE, Ackroyd R. 5-Aminolaevulinic acid-induced photodynamic therapy and photodetection in Barrett's esophagus. Dis Esophagus 2004; 17: 205-12.
113. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: part one-photosensitizers, photochemistry and cellular localization. Photodiagn Photodyn Ther 2004; 1: 279-93.
114. Saw CLL, Olivo M, Chin WWL, Soo KC, Heng PWS. Superiority of N-methyl pyrrolidone over albumin with hypericin for fluorescence diagnosis of human bladder cancer cells implanted in the chick chorioallantoic membrane model. J Photochem Photobiot B 2007; 86: 207-18.
115. Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem Photobiol 1995; 61: 529-39.
116. Hun X, Zhang ZJ, Tiao L. Anti-Her-2 monoclonal antibody conjugated polymer fluorescent nanoparticles probe for ovarian cancer imaging. Anal Chim Acta 2008; 625: 201-6.
117. Liu T, Zhang G, Chen YH, et al. Tissue specific expression of suicide genes delivered by nanoparticles inhibits gastric carcinoma growth. Cancer Biol Ther 2006; 5: 1683-90.
118. Sawicki JA, Anderson DG, Langer R. Nanoparticle delivery of suicide DNA for epithelial ovarian cancer therapy. Adv Exp Med Biol 2008; 622: 209-19.
119. Kaul G, Amiji M. Tumor-targeted gene delivery using poly(ethylene glycol)-modified gelatin nanoparticles: In vitro and in vivo studies. Pharm Res 2005; 22: 951-61.
120. Yadav S, van Vlerken LE, Little SR, Amiji MM. Evaluations of combination MDR-1 gene silencing and paclitaxel administration in biodegradable polymeric nanoparticle formulations to overcome multidrug resistance in cancer cells. Cancer Chemother Pharmacol 2009; 63: 711-22.
121. Tamura T, Sakata T. Application of in vivo electroporation to cancer gene therapy. Curr Gene Ther 2003; 3: 59-64.
122. Unger EC, Matsunaga TO, McCreery T, et al. Therapeutic applications of microbubbles. Eur J Radiol 2002; 42: 160-8.
123. Bhatia VK, Senior R. Contrast echocardiography: evidence for clinical use. J Am Soc Echocardiogr 2008; 21: 409-16.
124. Villanueva FS. Molecular imaging of cardiovascular disease using ultrasound. J Nucl Cardiol 2008; 15: 576-86.
125. Abramowicz JS. Ultrasonographic contrast media - Has the time come in obstetrics and gynecology? J Ultrasound Med 2005; 24: 517-31.
126. Taniyama Y, Morishita R. Development of plasmid DNA-based gene transfer. Yakugaku Zasshi 2006; 126: 1039-45.
127. Wang JF, Wang JB, Chen H, et al. Ultrasound-mediated microbubble destruction enhances gene transfection in pancreatic cancer cells. Adv Ther 2008; 25: 412-21.
128. Cristiano RJ. Protein/DNA polyplexes for gene therapy. Surg Oncol Clin N Am 2002; 11: 697-716, viii.
129. Cristiano RJ, Curiel DT. Strategies to accomplish gene delivery via the receptor-mediated endocytosis pathway. Cancer Gene Ther 1996; 3: 49-68.
130. Cheng PW. Receptor ligand-facilitated gene transfer: enhancement of liposome-mediated gene transfer and expression by transferrin. Hum Gene Ther 1996; 7: 275-82.
131. Antony AC. Folate receptors. Annu Rev Nutr 1996; 16: 501-21.
132. Lee RJ, Low PS. delivery of liposomes into cultured Kb cells via folate receptor-mediated endocytosis. J Biol Chem 1994; 269: 3198-204.
133. Chang EH, Xu L, Pirollo KF. Targeted p53 gene therapy-mediated radiosensitization and chemosensitization, in signaling networks and cell cycle control: the molecular basis of cancer and other diseases. Gutkind JS, Ed. USA: Humana Press 1999; pp. 519-36.
134. van Zanten-Przybysz I, Molthoff C, Gebbinck JK, et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. J Cancer Res Clin 2002; 128: 484-92.
135. Van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: I.v. vs. i.p. Int J Cancer 2001; 92: 106-14.
136. van Zanten-Przybysz I, Molthoff CF, Roos JC, et al. Radioimmunotherapy with intravenously administered I-131-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. J Nucl Med 2000; 41: 1168-76.
137. Wang S, Lee RJ, Cauchon G, Gorenstein DG, Low PS. Delivery of antisense oligodeoxyribonucleotides against the human epidermal growth-factor receptor into cultured Kb cells with liposomes conjugated to folate Via polyethylene-glycol. Proc Natl Acad Sci USA 1995; 92: 3318-22.
138. Rait AS, Pirollo KF, Xiang LM, Ulick D, Chang EH. Tumor-targeting, systemically delivered antisense HER-2 chemosensitizes human breast cancer xenografts irrespective of HER-2 levels. Mol Med 2002; 8: 475-86.
139. Xu LN, Pirollo KF, Chang EH. Transferrin-liposome-mediated p53 sensitization of squamous cell carcinoma of the head and neck to radiation in vitro. Hum Gene Ther 1997; 8: 467-75.
140. Xu LA, Pirollo KF, Tang WH, Rait A, Chang EH. Transferrin-liposome- mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. Hum Gene Ther 1999; 10: 2941-52.
141. Penacho N, Filipe A, Simoes S, de Lima MCP. Transferrin-associated lipoplexes as gene delivery systems: relevance of mode of preparation and biophysical properties. J Membr Biol 2008; 221: 141-52.
142. Simoes S, Slepushkin V, Gaspar R, de Lima MCP, Duzgunes N. Gene delivery by negatively charged ternary complexes of DNA, cationic liposomes and transferrin or fusigenic peptides. Gene Ther 1998; 5: 955-64.
143. Erbacher P, Remy JS, Behr JP. Gene transfer with synthetic virus-like particles via the integrin-mediated endocytosis pathway. Gene Ther 1999; 6: 138-45.
144. Diebold SS, Kursa P, Wagner E, Cotten M, Zenke M. Mannose polyethylenimine conjugates for targeted DNA delivery into dendritic cells. J Biol Chem 1999; 274: 19087-94.
145. Cristiano RJ. Viral and non-viral vectors for cancer gene therapy. Anticancer Res 1998; 18: 3241-5.
146. Pan XQ, Wang HQ, Lee RJ. Antitumor activity of folate receptor-targeted liposomal doxorubicin in a KB oral carcinoma murine xenograft model. Pharm Res 2003; 20: 417-22.
147. Kelley KMM, Rowan BG, Ratnam M. Modulation of the folate receptor alpha gene by the estrogen receptor: mechanism and implications in tumor targeting. Cancer Res 2003; 63: 2820-8.
148. Wang H, Zheng X, Behm FG, Ratnam M. Differentiation-independent retinoid induction of folate receptor type beta, a potential tumor target in myeloid leukemia. Blood 2000; 96: 3529-36.
149. Dachs GU, Patterson AV, Firth JD, et al. Targeting gene expression to hypoxic tumor cells. Nat Med 1997; 3: 515-20.
150. Huang Q, Hu JK, Lohr F, et al. Heat-induced gene expression as a novel targeted cancer gene therapy strategy. Cancer Res 2000; 60: 3435-9.
151. Chung I, Schwartz PE, Crystal RG, et al. Use of L-plastin promoter to develop an adenoviral system that confers transgene expression in ovarian cancer cells but not in normal mesothelial cells. Cancer Gene Ther 1999; 6: 99-106.
152. Bao RD, Selvakumaran M, Hamilton TC. Targeted gene therapy of ovarian cancer using an ovarian-specific promoter. Gynecol Oncol 2002; 84: 228-34.
153. Barker SD, Coolidge CJ, Kanerva A, et al. The secretory leukoprotease inhibitor (SLPI) promoter for ovarian cancer gene therapy. J Gene Med 2003; 5: 300-10.
154. Breidenbach M, Rein DT, Everts M, et al. Mesothelin-mediated targeting of adenoviral vectors for ovarian cancer gene therapy. Gene Ther 2005; 12: 187-93.
155. Robertson MW, Wang MH, Siegal GP, et al. Use of a tissue-specific promoter for targeted expression of the herpes simplex virus thymidine kinase gene in cervical carcinoma cells. Cancer Gene Ther 1998; 5: 331-6.
156. Tanyi JL, Lapushin R, Eder A, et al. Identification of tissue- and cancer-selective promoters for the introduction of genes into human ovarian cancer cells. Gynecol Oncol 2002; 85: 451-8.
157. Berry NB, Cho YM, Harrington MA, et al. Transcriptional targeting in ovarian cancer cells using the human epididymis protein 4 promoter. Gynecol Oncol 2004; 92: 896-904.
158. Robbins J, Dilworth SM, Laskey RA, Dingwall C. Two interdependent basic domains in nucleoplasmin nuclear targeting sequence: identification of a class of bipartite nuclear targeting sequence. Cell 1991; 64: 615-23.
159. Aronsohn AI, Hughes JA. Nuclear localization signal peptides enhance cationic liposome-mediated gene therapy. J Drug Target 1998; 5: 163-9.
160. Duvshani-Eshet M, Keren H, Oz S, et al. Effect of peptides bearing nuclear localization signals on therapeutic ultrasound mediated gene delivery. J Gene Med 2008; 10: 1150-9.
161. Branden LJ, Mohamed AJ, Mith CIE. A peptide nucleic acid-nuclear localization signal fusion that mediates nuclear transport of DNA. Nat Biotechnol 1999; 17: 784-7.
162. Dean DA, Dean BS, Muller S, Smith LC. Sequence requirements for plasmid nuclear import. Exp Cell Res 1999; 253: 713-22.
163. Young JL, Benoit JN, Dean DA. Effect of a DNA nuclear targeting sequence on gene transfer and expression of plasmids in the intact vasculature. Gene Ther 2003; 10: 1465-70.
164. Vaysse L, Gregory LG, Harbottle RP, et al. Nuclear-targeted minicircle to enhance gene transfer with non-viral vectors in vitro and in vivo. J Gene Med 2006; 8: 754-63.
165. Oupicky D, Ogris M, Seymour LW. Development of long-circulating polyelectrolyte complexes for systemic delivery of genes. J Drug Target 2002; 10: 93-8.
166. Oupicky D, Ogris M, Howard KA, et al. Importance of lateral and steric stabilization of polyelectrolyte gene delivery vectors for extended systemic circulation. Mol Ther 2002; 5: 463-72.
167. Markman M. Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin Pharmacol 2006; 7: 1469-74.
168. Strauss HG, Hemsen A, Karbe I, et al. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anti-Cancer Drug 2008; 19: 541-5.
169. Pignata S, Scambia G, Savarese A, et al. Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer: preliminary activity results of the MITO-2 phase III trial. Oncology 2009; 76: 49-54.
170. Maeda H. The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv Enzyme Regul 2001; 41: 189-207.
171. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm 2009; 71: 409-19.
172. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006; 1: 297-315.
173. Allen TM, Hansen C. Pharmacokinetics of Stealth Versus Conventional Liposomes - Effect of Dose. Biochim Biophys Acta 1991; 1068: 133-41.
174. Mahmood I, Green MD. Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins. Clin Pharmacokinet 2005; 44: 331-47.
175. Rose PG. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer. Oncologist 2005; 10: 205-14.
176. Alberts DS, Liu PY, Wilczynski SP, et al. Randomized trial of pegylated liposomal doxorubicin (PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial platinum-based chemotherapy (Southwest Oncology Group Protocol S0200). Gynecol Oncol 2008; 108: 90-4.
177. Fujiwara T, Tanaka N, Kanazawa S, et al. Multicenter phase I study of repeated intratumoral delivery of adenoviral p53 in patients with advanced non-small-cell lung cancer. J Clin Oncol 2006; 24: 1689-99.
178. Li ZB, Zeng ZJ, Chen Q, Luo SQ, Hu WX. Recombinant AAV-mediated HSVtk gene transfer with direct intratumoral injections and Tet-On regulation for implanted human breast cancer. BMC Cancer 2006; 6: 66.
179. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a Phase II trial. Cancer Res 2000; 60: 6359-66.
180. Vasey PA, Seiden MV, O'Neill V, et al. Phase I trial of intraperitoneal Onyx-015 adenovirus in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 2000; 19: abstract 1512.
181. Friberg G, Fleming G. Intraperitoneal chemotherapy for ovarian cancer. Nemunaitis 2003; 5: 447-53.
182. Madhusudan S, Tamir A, Bates N, et al. A Multicenter phase I gene therapy clinical trial involving intraperitoneal administration of E1A-lipid complex in patients with recurrent epithelial ovarian cancer overexpressing HER-2/neu oncogene. Clin Cancer Res 2004; 10: 2986-96.
183. Stiewe T, Parssanedjad K, Esche H, Opalka B, Putzer BM. E1A overcomes the apoptosis block in BCR-ABL plus leukemia cells and renders cells susceptible to induction of apoptosis by chemotherapeutic agents. Cancer Res 2000; 60: 3957-64.
184. Ueno NT, Bartholomeusz C, Herrmann JL, et al. E1A-mediated paclitaxel sensitization in HER-2/neu-overexpressing ovarian cancer SKOV3.ip1 through apoptosis involving the caspase-3 pathway. Clin Cancer Res 2000; 6: 250-9.
185. Isayeva T, Ren C, Ponnazhagan S. Intraperitoneal gene therapy by rAAV provides long-term survival against epithelial ovarian cancer independently of survivin pathway. Gene Ther 2007; 14: 138-46.
186. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43.
187. Liu Y, Liggitt D, Zhong W, et al. Cationic liposome-mediated intravenous gene delivery. J Biol Chem 1995; 270: 24864-70.
188. Wang XP, Yazawa K, Templeton NS, et al. Intravenous delivery of liposome-mediated nonviral DNA is less toxic than intraperitoneal delivery in mice. World J Surg 2005; 29: 339-43.
189. Duvillard C, Polycarpe E, Romanet P, Chauffert B. Intratumoral chemotherapy: experimental data and applications to head and neck tumors. Annales d Oto-Laryngologie et de Chirurgie Cervico-Faciale 2007; 124: 53-60.
190. Landen CN, Merritt WM, Mangala LS, et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006; 5: 1708-13.
191. Shin KS, Sullenger BA, Lee SW. Ribozyme-mediated induction of apoptosis in human cancer cells by targeted repair of mutant p53 RNA. Mol Ther 2004; 10: 365-72.
192. Thasni KAA, Rojini G, Rakesh SN, et al. Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. Eur J Pharmacol 2008; 588: 158-64.
193. Pack SD, Alper OM, Stromberg K, et al. Simultaneous suppression of epidermal growth factor receptor and c-erbB-2 reverses aneuploidy and malignant phenotype of a human ovarian carcinoma cell line. Cancer Res 2004; 64: 789-94.
194. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Chemosensitization of carcinoma cells using epithelial cell adhesion molecule-targeted liposomal antisense against bcl-2/bcl-xL. Mol Cancer Ther 2006; 5: 3170-80.
195. Park HY. Inhibition of the proliferative effect of transforming growth factor-alpha by c-myc antisense DNA in human ovarian cancer cells. Biochem Mol Biol Int 1997; 43: 1015-22.
196. Kushner DM, Paranjape JM, Bandyopadhyay B, et al. 2-5A antisense directed against telomerase RNA produces apoptosis in ovarian cancer cells. Gynecol Oncol 2000; 76: 183-92.
197. Hirota Y, Osuga Y, Nose E, et al. The presence of midkine and its possible implication in human ovarian follicles. Am J Reprod Immunol 2007; 58: 367-73.
198. Strait KA, Dabbas B, Hammond EH, et al. Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 2002; 1: 1181-90.
199. Hyde CAC, Missailidis S. Inhibition of arachidonic acid metabolism and its implication on cell proliferation and tumourangiogenesis. Int Immunopharmacol 2009; 9: 701-15.
200. Adjei AA. Ras signaling pathway proteins as therapeutic targets. Curr Pharm Des 2001; 7: 1581-94.
201. Kunze D, Wuttig D, Kausch I, et al. Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo. Int J Oncol 2008; 32: 1049-56.
202. Noske A, Lindenberg JL, Darb-Esfahani S, et al. Activation of mTOR in a subgroup of ovarian carcinomas: correlation with peIF-4E and prognosis. Oncol Rep 2008; 20: 1409-17.
203. Lin CC, Yen MC, Lin CM, et al. Delivery of noncarrier naked DNA vaccine into the skin by supersonic flow induces a polarized T helper type 1 immune response to cancer. J Gene Med 2008; 10: 679-89.
204. Dietrich A, Becherer L, Brinckmann U, et al. Particle-mediated cytokine gene therapy leads to antitumor and antimetastatic effects in mouse carcinoma models. Cancer Biother Radio 2006; 21: 333-41.
205. Tanigawa K, Yu H, Sun R, Nickoloff BJ, Chang AE. Gene gun application in the generation of effector T cells for adoptive immunotherapy. Cancer Immunol Immun 2000; 48: 635-43.
206. Rakhmilevich AL, Hooper AT, Hicklin DJ, Sondel PM. Treatment of experimental breast cancer using interleukin-12 gene therapy combined with anti-vascular endothelial growth factor receptor-2 antibody. Mol Cancer Ther 2004; 3: 969-76.
207. Li XS, Wang ZG, Ran HT, et al. Experimental research on therapeutic angiogenesis induced by hepatocyte growth factor directed by ultrasound-targeted microbubble destruction in rats. J Ultrasound Med 2008; 27: 453-60.
208. Bekeredjian R, Kroll RD, Fein E, et al. Ultrasound targeted microbubble destruction increases capillary permeability in hepatomas. Ultrasound Med Biol 2007; 33: 1592-8.
209. Sonoda S, Tachibana K, Uchino E, et al. Gene transfer to corneal epithelium and keratocytes mediated by ultrasound with microbubbles. Invest Ophthalmol Vis Sci 2006; 47: 558-64.
210. Koike H, Tomita N, Azuma H, et al. An efficient gene transfer method mediated by ultrasound and microbubbles into the kidney. J Gene Med 2005; 7: 108-16.
211. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21: 247-57.
212. Chen RF, Li ZH, Pan QH, et al. In vivo radioiodide imaging and treatment of pancreatic cancer xenografts after MUC1 promoter driven expression of the human sodium-iodide symporter. Pancreatology 2007; 7: 505-13.
213. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483-9.
214. Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC. Sodium iodide symporter-mediated radioiodide imaging and therapy of ovarian tumor xenografts in mice. Gene Ther 2006; 13: 60-6.